PSMB9 and cancer: Chymotrypsin-like proteasome activities are inhibited by systemic exposure with chemotherapeutics in anti-cancer therapy (Thibaudeau and Smith, 2019), which primarily affects subunits β5, Lmp2 and Lmp7 in the heart (Besse et al., 2019).